AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05891795
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apply a thin layer to the affected area twice daily.
Trial: NCT06196671
Drug: H101
RxNorm normalized name: Avicel PH101 (Microcrystalline Cellulose NF) for Compounding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H101 15x10\^11vp intratumorally injection starts at day 1.
Trial: NCT05682482
Drug: LT3 (liothyronine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Addition of liothyronine (LT4/LT3 combination therapy) in patients with persistent tiredness on LT4 monotherapy. To investigate whether addition of LT3 is effective in relieving tiredness.
Trial: NCT05682482
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Addition of placebo (LT4 monotherapy) in patients with persistent tiredness on LT4 monotherapy.
Trial: NCT05660980
Drug: Long acting CAB injectable + long acting RPV injectable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injectable
Trial: NCT05212818
Drug: TF0023
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Techfields Inc. is developing TF0023, a new investigational prodrug, indicated for relief of the signs and symptoms of ARDS and pneumonia caused by COVID-19 and other viruses.
Trial: NCT06262607
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical vehicle gel administered once daily
Trial: NCT05949502
Drug: Beautifil II LS (Low-Shrinkage)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: low shrinkage bioactive material Giomer
Trial: NCT05949502
Drug: 3M Filtek Z250 XT Universal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Universal Nano-hybrid composite
Trial: NCT06023641
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-risk Administer by IV infusion over 30-60 minutes on Day 1, 91) dose, Mesna and hydration will be given with IV cyclophosphamide according to institutional standards.~Intermediate-risk Administer by IV infusion over 30-60 minutes, 1 dose, day 1 High-risk Administer by IV infusion over 30-60 minutes, 1 dose, day1
Trial: NCT05048524
Drug: S-1, leucovorin, oxaliplatin and gemcitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 800 mg/m2 on day 1, oxaliplatin 85 mg/m2 on day 1, S-1 orally 80-120 mg/day \[depending on patient's body surface area (BSA)\] on day 1 to 7 and leucovorin 30mg BID day 1 to 7 on in a 2-week cycle. The dose of S-1 is defined as follows:~* BSA \< 1.25 m2: 80 mg/day~* 1.25 m2 ≤ BSA \< 1.5 m2: 100 mg/day~* BSA ≥ 1.5 m2: 120 mg/day
Trial: NCT05618691
Drug: GFH312
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet, GFH312 will be administered at 3 dose levels, each patient in one of three groups will be given a dose of 40mg, 80mg, 120mg of the study drug.
Trial: NCT06190197
Drug: Prophylactic antibiotics postoperatively.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic antibiotics postoperatively. All participants in this arm will receive nitrofurantoin 100 milligrams by mouth daily for either 10 or 21 days based on whether they had an ileal conduit or orthotopic neobladder, respectively, for the diversion. Participants will be instructed to swallow the capsule whole, preferably with food and at the same time each day. If a dose is forgotten, participants will be asked to take it when they remember and then take the next dose as usual. However, if they do not remember until the next dose, do not take extra capsules to make up the missed dose.
Trial: NCT05686044
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPMC (vegetarian source) capsule shells
Trial: NCT05219370
Drug: Cannabis oil
RxNorm normalized name: Cannabis oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administration of different cannabis oil types as compared with placebo
Trial: NCT00000771
Drug: Paromomycin sulfate
RxNorm normalized name: Paromomycin Sulfate
DrugBank: Paromomycin (DB01421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04986436
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single or multiple dose(s) of Placebo
Trial: NCT05002244
Drug: CTL0801 (Azilsartan)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTL0801 (Azilsartan), single dose, daily, repeated oral administration
Trial: NCT05002244
Drug: CTL0802 (Rosuvastatin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTL0802 (Rosuvastatin), single dose, daily, repeated oral administration
Trial: NCT05002244
Drug: CTL0801 (Azilsartan) + CTL0802 (Rosuvastatin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTL0801 (Azilsartan) + CTL0802 (Rosuvastatin), single dose, daily, repeated oral administration
Trial: NCT06205615
Drug: BXP154B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BXP154B will be self-administered topically following wound induction
Trial: NCT06205615
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be self-administered topically following wound induction
Trial: NCT06003348
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05007652
Drug: KRN125(pegfilgrastim), PLR001(plerixafor)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.2 mg of KRN125 in Day 1 Single subcutaneous administration The concomitant drug PLR001 is administered subcutaneously once daily at a dose of 0.24 mg/kg when meets the criteria. The dosing period is 12-9 hours before apheresis on the following day.
Trial: NCT05007652
Drug: KRN8601(filgrastim), PLR001(plerixafor)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 ug/m2 of KRN8601 from Day 1 to the end date of the Apheresis Once daily subcutaneous administration The concomitant drug PLR001 is administered subcutaneously once daily at a dose of 0.24 mg/kg when meets the criteria. The dosing period is 12-9 hours before apheresis on the following day.
Trial: NCT05865041
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets administered orally
Trial: NCT05433844
Drug: Reference Drug or Test Drug
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test Drug: single administration of JW0301 Reference Drug: single administration of C2105~Tablet, Oral, QD for 1 Days, Washout period is more than 14 days after administration
Trial: NCT00669123
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00261404
Drug: TNFerade™
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05753592
Drug: Part 1; LOU064 (Remibrutinib)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg remibrutinib (5.5 days)
Trial: NCT05753592
Drug: Part 2; LOU064 (Remibrutinib)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg remibrutinib (5.5 days)
Trial: NCT04888377
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participant's mothers were administered placebo throughout their pregnancy with the participant.
Trial: NCT04762719
Drug: PET/CT Scan with 11C-ER176
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will have a low-dose, non-gated, non-contrast-enhanced, free-breathing CT from the orbits to upper thigh for attenuation correction (CTAC) and anatomic co-localization. Immediately following the start of the PET scan, 518 MBq (14 mCi) (range 370-666 MBq; 10-18 mCi) of 11C-ER 176 will be administered intravenously followed by a saline flush. A whole-body PET scan from the orbits to upper thigh will then be acquired.
Trial: NCT06072612
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide is an alkylating agent with indications for treatment of malignant diseases including breast cancer. Cyclophosphamide (Cytoxan) 300 mg/m2 I.V., single dose, will be given to patients assigned to the SV-BR-1-GM. Cyclophosphamide will be administered 2-3 days prior to SV-BR-1-GM inoculations.
Trial: NCT06072612
Drug: Treatment of Physician's Choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the TPC arm of the study will be treated with one or a combination of the following: carboplatin, taxanes, capecitabine, gemcitabine, vinorelbine or eribulin in accordance with the investigators and institutional standard of care. For HER2+ patients, a HER2-targeted agent of the physician's choice can be part of TPC.
Trial: NCT06362707
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets that look identical to the fasudil tablets and will follow the same dosing schedule as participants receiving fasudil.
Trial: NCT05878262
Drug: ibuprofen suppository
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: After the induction of anesthesia was performed, the nurse delivered the ibuprofen suppository at the dose of 5-10 mg/Kg for the pre-emptive analgesia group children.
Trial: NCT06080178
Drug: Plasma-lyte (static group)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasmalyte will be administered intravenously: (1) as a maintenance infusion 1ml/kg/h (from anaesthesia induction until ICU/PACU discharge); (2) as a fluid bolus until 5ml/kg/h crystalloid (without maintenance infusion) is reached or until SBP is above 100mmHg
Trial: NCT06080178
Drug: Norepinephrine (static group)
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: When during surgery SBP is below 100mmHg, if the 5ml/kg/h crystalloid limit is already reached, start or increase norepinephrine infusion until SBP is above 100mmHg (with a maximum dose of 0.2mcg/kg/min).
Trial: NCT06080178
Drug: Plasma-lyte (dynamic group)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasmalyte will be administered intravenously:~(1) as a maintenance infusion 1 ml/kg/h (from anaesthesia induction until ICU/PACU discharge); (2) as a fluid bolus until PPV is below or equal to 12% or SBP is above 100mmHg.
Trial: NCT06348290
Drug: JMKX001899
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT06348290
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral
Trial: NCT06080178
Drug: Norepinephrine (dynamic group)
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: When during surgery SBP is below 100mmHg and PPV is below or equal to 12%: start or increase norepinephrine infusion until SBP is above 100mmHg (with a maximum dose of 0.2mcg/kg/min).~When SBP is above 120mmHg: decrease the norepinephrine infusion rate until SBP is below 120mmHg.
Trial: NCT05224167
Drug: Melatonin 5 MG Sublingual Tablet
RxNorm normalized name: melatonin 5 MG Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 5 mg 12 hours and 2 hours prior to surgery
Trial: NCT06096909
Drug: Cholesterol Absorption Inhibitor
RxNorm normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholesterol absorption inhibitors (like Ezetimibe and Hybutimibe) are based on physician decisions, but need to be routinely dosed. Examples of Medications that Meet Study Requirements: Ezetimibe 10mg Po qd.
Trial: NCT06096909
Drug: Statin
RxNorm normalized name: Statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin are based on physician decisions, but need to be routinely dosed. Examples of Medications that Meet Study Requirements: Atorvastatin 20mg Po qn, Rosuvastatin 10mg Po qn or Pitavastatin 4mg Po qn.
Trial: NCT06141356
Drug: [18F]Florbetazine ([18F]92)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single intravenous bolus injection of 10 mCi ± 20% of the investigational radiotracer \[18F\]Florbetazine and will undergo a PET/CT scan.
Trial: NCT06141356
Drug: [11C]PIB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single intravenous bolus injection of 6.0-20.0mCi of the investigational radiotracer \[11C\]PIB and will undergo a PET/CT scan.
Trial: NCT05300438
Drug: TSN084
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets
Trial: NCT01076439
Drug: Saline Nasal Spray
RxNorm normalized name: Saline Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04448028
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with a pre-existing PPI therapy discontinue PPI therapy and replace it with placebo over a period of 346 days after a 14 day dose tapering phase.
Trial: NCT04880291
Drug: GFB-024
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peripherally acting Cannabinoid-1 receptor inverse agonist monoclonal antibody
Trial: NCT04880291
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo
Trial: NCT05439213
Drug: Adrenaline 0,33 Mg/mL Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: adrenaline dosage
Trial: NCT05439213
Drug: Adrenaline 1 Mg/mL Solution for Injection
RxNorm normalized name: Adrenaline 1 mg/mL solution for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: adrenaline dosage
Trial: NCT05126251
Drug: Tangningtongluo tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tangningtongluo Tablet is an in-hospital preparation of Guizhou bailing. It is used for diabetes caused by deficiency of Qi and Yin. The symptoms include thirst, drinking, overeating, polyuria, weight loss, shortness of breath, fatigue, hand, foot and heart heat and blurred vision; Type 2 diabetes and diabetic retinopathy see the above syndrome. The present study shows that Tangningtongluo Tablet have certain hypoglycemic effects in diabetic animal models and diabetic patients, and may improve insulin sensitivity in diabetic mice.It is speculated that the drug may be effective for prediabetes. (0.4g/tablet,Plate(12 pills/plate ×3 plates/box))
Trial: NCT05020015
Drug: Chemotherapy Agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine and cyclophosphamide as per standard of care.
Trial: NCT05732103
Drug: CTX-712
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTX-712 will be provided as a 20 mg tablet for oral administration. Patients will take CTX-712 weekly, depending on their dose level assignment, during each 28-day cycle.
Trial: NCT05705349
Drug: DOR/ISL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose combination tablet containing DOR/ISL 100 mg/0.25 mg taken by mouth.
Trial: NCT06370884
Drug: IMT
RxNorm normalized name: Imtack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a feeding tube placed at the time of surgery and receive IMT solution on postoperative day 2-3 (at least 48 hours following IV antibiotics) with the subsequent removal of the feeding tube.
Trial: NCT05181189
Drug: DAOIB+Omega-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The omega-3 fatty acids dose will be adjusted every 8 weeks according to clinical evaluation.
Trial: NCT05181189
Drug: DAOIB+Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05749432
Drug: Hemay181
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemay181 will be given intravenously on the first day per cycle, and the treatment cycle is 21-days.
Trial: NCT02614352
Drug: AG1502
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05182840
Drug: Placebo to BI 690517
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film-coated tablets
Trial: NCT05022121
Drug: Medical Care
RxNorm normalized name: benzethonium Medicated Liquid Soap [Bedside-Care]
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical care will be comprised of primarily medication management, which is a standard first-line approach for back-related leg pain in primary care. Choice of medications is informed by the current evidence and the American College of Physicians guidelines on noninvasive treatment for LBP which balances evidence for risks and benefits when making recommendations. Decisions regarding medication selection will be made collaboratively between the study provider and patient after a discussion of risk/benefit profiles and patient preferences, including prior response. Study providers licensed to prescribe FDA-approved medications will call-in the prescription for the medication of choice to the participant's preferred pharmacy, as is typical in clinical practice.
Trial: NCT04708236
Drug: ORTD-1 mid dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ORTD-1 will be administered intravenously once daily for 5 consecutive days.
Trial: NCT04744090
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (identical to roflumilast dosage form) will be used for placebo-comparator group.
Trial: NCT04901689
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00248963
Drug: Levonorgestrel 90 mg and Ethinyl Estradiol 20 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04795336
Drug: Melatonin 5 mg
RxNorm normalized name: melatonin 5 MG
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Melatonin is a widely sold synthetic molecule in various forms including tablets, gummies and liquid. In the present study, the tablet version of the medication will be used at a dose of 5mg
Trial: NCT04478734
Drug: Moderate doses of Thiamine y Biotin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiamine 600 mg every day + Biotin 150mg every day
Trial: NCT00742833
Drug: KUC-7483
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00742833
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04812262
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo drug of DD01, administered in a 1mL volume for injection
Trial: NCT05166837
Drug: STSA-1002 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection
Trial: NCT05166837
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection
Trial: NCT04784442
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo, tablet, once daily, for 12 weeks
Trial: NCT05969847
Drug: CAPOX
RxNorm normalized name: Capecitabine and Oxaliplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Oxaliplatin,130mg/m2，ivgtt，d1,for 6 cycles. Drug: Capecitabine,1000mg/m2，po，bid，d1-14, for 6 cycles.
Trial: NCT03235232
Drug: BREMEN eye drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop in the affected eye(s), twice a day (approximately each 12 hours) for 8 weeks.
Trial: NCT03235232
Drug: Combigan®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop of Combigan® in the affected eye(s), twice a day (approximately each 12 hours) for 8 weeks.
Trial: NCT05509868
Drug: PBK_L1704 0.35mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subject will receive PBK_L1704 0.35mg/ml by PCA
Trial: NCT05509868
Drug: PBK_L1704 0.5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subject will receive PBK_L1704 0.5mg/ml by PCA
Trial: NCT05509868
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subject will receive placebo by PCA
Trial: NCT04500847
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg daily oral dose
Trial: NCT06478381
Drug: L218CAR19
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L218CAR19 is intravenously administered at three dose levels.
Trial: NCT04665089
Drug: Erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Before each intervention (either at inclusion: day 0) and after the end of 5 days of erythromycin or placebo (day 6), the following dosages will be performed:~* Pro-inflammatory cytokine (TNF alpha)~* Anti-inflammatory cytokine (IL-10)~* Procalcitonin (PCT) Then, analysis of the variations in the TNF/ IL-10 ratio, the blood count, CRP and PCT parameters (between Day 0 and Day 6)
Trial: NCT04492488
Drug: MRG002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administrated intravenously
Trial: NCT05348278
Drug: Urea cream
RxNorm normalized name: Amino Acid-Urea Cream
DrugBank: Urea (DB03904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: apply 10% urea cream at both hands and feet twice daily
Trial: NCT05127746
Drug: DA-5207 B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 patch once weekly
Trial: NCT06578078
Drug: Standard of care treatment (RAASi therapy)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care treatment (RAASi therapy) without use of sodium zirconium cyclosilicate
Trial: NCT04825730
Drug: JOINTSTEM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JOINTSTEM is an OA treatment that uses autologous adipose-derived mesenchymal stem cells. As it does not use allogenic tissues and is incubated without additional genetic modification or mechanical and chemical modification through differentiation, it is classified as 'autologous cell therapy' and is completely free of immunologic rejection.
Trial: NCT05657574
Drug: D086
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral, once daily, 8 weeks
Trial: NCT05657574
Drug: Placebo (for D377)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral, once daily, 8 weeks
Trial: NCT05657574
Drug: Placebo (for CKD-331)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral, once daily, 8 weeks
Trial: NCT05657574
Drug: Placebo (for D086)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral, once daily, 8 weeks
Trial: NCT05983250
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06286878
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be randomized to use dapagliflozin or placebo in a double-blind way
Trial: NCT04893915
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: -Lymphodepleting regimen
Trial: NCT06650332
Drug: XELOX
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxaliplatin: 130 mg/m\\(\^2\\), IV, D1; Capecitabine: 1000 mg/m\\(\^2\\), oral (PO), twice daily, D1-14.